Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q4 FY20 Earnings Presentation
13 slides from Alkem Laboratories's earnings presentation, Jun 5, 2020
Slide 1: Investor Presentation Q4FY20
Investor Presentation Q4FY20 June 5, 2020
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Key Highlights of Q4FY20 and FY20
Key Highlights of Q4FY20 and FY20 Steady revenue growth accompanied by improvement in EBITDA margin • Revenue from Operations in Q4FY20 grew by 10.6% YoY, accompanied by 220bps YoY improvement in EBITDA margin. Adjusting for the delay in transportation due to lockdown in the month of March 2020, the
Slide 4: Key Financial Highlights – Q4FY20
Key Financial Highlights – Q4FY20 All figures in ₹ mn Revenue from Operations India sales 12,176 12,576 20,490 18,530 Q4FY19 Q4FY20 International sales 7,523 6,097 Q4FY19 Q4FY20 Q4FY19 Q4FY20
Slide 5: Key Financial Highlights – Q4FY20
Key Financial Highlights – Q4FY20 All figures in ₹ mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 11,546 3,030 10,775 2,338 58.1% 56.4% 12.6% 14.8% Q4FY19 Q4FY20 Q4FY19 Q4FY20 PBT (before Minority Interest) PAT (after Minority Interest) 1,888 2,353 1,674 1,988 Q4FY19 Q4FY20 Q4FY19 Q4FY20
Slide 6: Key Financial Highlights
Key Financial Highlights Consolidated Financials Particulars (₹ mn) FY20 FY19 YoY growth Revenue from Operations 83,444 73,572 13.4% Gross Profit 49,994 44,122 13.3% Gross Profit margin 59.9% 60.0% EBITDA 14,734 11,148 32.2% EBITDA margin 17.7% 15.2% PBT 12,598 9,547 32.0% PBT margin 15.1% 13.0% PAT
Slide 7: India Business
India Business India Business: Q4FY20 Sales of ₹ 12,576 million (3.3% YoY growth) • India sales contributed 62.6% to total sales in Q4FY20 • In Q4FY20, Company’s secondary sales grew by 8.8% YoY vs. IPM growth of 9.6% YoY. In FY20, the Company’s secondary sales grew ahead of the IPM with growth of 1
Slide 8: Secondary Sales Performance
Secondary Sales Performance Established therapeutic Outperformance across most of the major therapeutic areas in FY20 Market rank 1 3 3 4 areas of Alkem 21.4% 20.7% 13.3% 11.6% 10.8% 10.8% 10.0% 8.7% Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients Alkem sales growth
Slide 9: US Business
US Business US Business: Q4FY20 Sales of ₹ 6,068 million (25.8% growth YoY) • US sales contributed 30.2% to total sales in Q4FY20 • Growth in US dollar terms was 22.7% YoY during the quarter - mainly driven by new product launches and market share gains • The US business crossed revenue milestone of
Slide 10: Update on the US FDA inspection
Update on the US FDA inspection EIR for all the six facilities inspected by the US FDA Facility Scope Last inspection Status post last inspection St. Louis (US) Formulation February 2020 EIR# received in May 2020, thereby successfully closing the inspection Baddi (India) Formulation February 2020 EI
Slide 11: Other International Business
Other International Business Other International Business: Q4FY20 Sales of ₹ 1,455 million (14.2% growth YoY) • Other International Market sales contributed 7.2% to total sales in Q4FY20 • The Company has presence in Australia, Europe, South East Asia, Latin America and Africa • Company’s key market
Slide 12: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on March 31, 2020 Non-Institution, 18.70% Institution, 15.41% Promoter & Promoter Group, 65.88% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other Bodi
Slide 13: Thank You
Thank You For further information or queries please contact Gagan Borana Investor Relations – Alkem Laboratories Ltd. Tel: +91 22 3982 9960 E-mail: gagan.borana@alkem.com